Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients.
about
Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factorsRuxolitinib: a new JAK1/2 inhibitor that offers promising options for treatment of myelofibrosis.Portal hypertension and myeloproliferative neoplasms: a relationship revealed.Patients with post-essential thrombocythemia and post-polycythemia vera differ from patients with primary myelofibrosis.Anti-Platelet Factor 4/Heparin Antibody Formation Occurs Endogenously and at Unexpected High Frequency in Polycythemia Vera.Multicenter Retrospective Analysis of Turkish Patients with Chronic Myeloproliferative Neoplasms.Role of treatment on the development of secondary malignancies in patients with essential thrombocythemia.Annual Clinical Updates in Hematological Malignancies: a continuing medical education series: polycythemia vera and essential thrombocythemia: 2011 update on diagnosis, risk-stratification, and management.Current outlook on molecular pathogenesis and treatment of myeloproliferative neoplasms.Pharmacological management of essential thrombocythemia.Paediatric essential thrombocythaemia: clinical and molecular features, diagnosis and treatment.Cytogenetic abnormalities in essential thrombocythemia at presentation and transformationMyeloproliferative neoplasms: from JAK2 mutations discovery to JAK2 inhibitor therapies.Treatment-related risk factors for transformation to acute myeloid leukemia and myelodysplastic syndromes in myeloproliferative neoplasmsHow I treat essential thrombocythemia.Patterns of survival among patients with myeloproliferative neoplasms diagnosed in Sweden from 1973 to 2008: a population-based study.Myeloproliferative Neoplasms in ChildrenRuxolitinib for myelofibrosis.Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial.Subcellular mislocalization of the transcription factor NF-E2 in erythroid cells discriminates prefibrotic primary myelofibrosis from essential thrombocythemia.Clinical relevance of JAK2 (V617F) mutant allele burdenImpact of JAK2V617F Mutational Status on Phenotypic Features in Essential Thrombocythemia and Primary Myelofibrosis.Clinical Features of 294 Turkish Patients with Chronic Myeloproliferative Neoplasms.Role of platelet counts in the management of essential thrombocythemia: experience with anagrelide.Myeloproliferative neoplasms 5 years after discovery of JAK2V617F: what is the impact of JAK2 inhibitor therapy?How to manage essential thrombocythemia.Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management.Biomarkers of deep venous thrombosis.BCR-ABL1-negative chronic myeloid neoplasms: an update on management techniques.Problems and pitfalls regarding WHO-defined diagnosis of early/prefibrotic primary myelofibrosis versus essential thrombocythemia.Thrombotic complications of myeloproliferative neoplasms: risk assessment and risk-guided management.Splanchnic vein thrombosis in myeloproliferative neoplasms.Cooperation between pathologists and clinicians allows a better diagnosis of Philadelphia chromosome-negative myeloproliferative neoplasms.Therapeutic apheresis for patients with cancer.Management of side effects of BCR/ABL-negative chronic myeloproliferative neoplasm therapies. Focus on anagrelide.How we diagnose and treat essential thrombocythaemia.Role of blood cells dynamism on hemostatic complications in low-risk patients with essential thrombocythemia.Leukemic transformation in essential thrombocythemia.Sequential analysis of 18 genes in polycythemia vera and essential thrombocythemia reveals an association between mutational status and clinical outcome.Essential thrombocythemia: a review of the clinical features, diagnostic challenges, and treatment modalities in the era of molecular discovery.
P2860
Q26777265-BD5AAE5E-8560-406E-9235-288B433FD358Q33397219-806C0A01-F868-4CAF-A108-64F83C77CD06Q33411130-44BF1FF6-4009-4B90-BF7F-AF320A135A12Q33442613-11234C8A-C6BB-4D8A-84C5-B5B2F63532F6Q33443580-AD78DAFF-DBF3-46C7-9AD0-1816C67B48FCQ33747797-42E67F9A-6956-40FE-9B1C-4A34AFD052B8Q33775211-21EB485A-EDCB-4A1D-8E93-CA607EA1AD2AQ34166859-883DEF16-DC75-436F-A648-4CFB3DFC5399Q34302770-A6662EDA-35B9-4A79-8C41-51BA8A2E6667Q34344384-A92C86A1-4AB6-40E0-8627-8B45CF1D80DAQ34370771-2D39AE53-1090-4C48-83B4-DD04F0238F72Q34405385-F3C9949C-2011-4694-A848-0B16A3088CCAQ34629928-E3F343A9-0DA0-4D84-B370-315E89FC737BQ35023473-51B489AC-0220-45AA-9621-33426B10F5F2Q35132271-411CD9BD-DF7C-481F-90D1-19D3AE78FE07Q36157668-B66B3729-3178-4D6E-9288-3BDD2EB23AC7Q36305041-A7FFFBA0-8233-4126-B5EC-8DAD2F76D14EQ36604028-0D14856D-E058-48B7-997B-E9A8638BD311Q36666769-E5D162CD-E68D-49CE-91D0-DE81EBB1BDBEQ36983755-889386FE-82FD-4263-83DE-8DC49EB79225Q37059441-33A552AB-8387-4157-82BC-9CFB4567B1EDQ37401358-BBB11F87-3D4E-4B30-B0D3-DEDB91C6F608Q37417438-7A5A0748-2DB2-4194-8D68-7E48A9F686F2Q37810089-28090372-3B4C-4C3C-B8D4-D24C599A3593Q37877727-349320FB-3C55-4151-9391-55F16E50976EQ37952488-A921344C-68D9-4C09-B528-5E67CC3515BDQ37983791-F5AB89CC-BFDA-4640-8E58-31E2119020A8Q38004988-87251335-CCCE-4DF7-905F-FBEA30D1BC63Q38014534-20068FE4-A914-4A3D-A1F6-267A6339E299Q38087202-7C66B240-67BA-4877-BBB8-698C1E9BD4E0Q38100371-99BF9822-4205-4E4F-9CC5-C1A32535BD4FQ38121635-262F610C-97E9-4AC5-8DF4-91BB48C13424Q38187675-9F1DAE90-68CD-45FD-99F1-84E35F00D225Q38287610-EF0A812A-B538-4DE8-9109-1E58DA9ADE92Q38586505-1E932E33-ADE3-4A7D-AEB6-55E1B095E002Q38606595-CAA8E261-AA78-43A1-9B0D-035E3B14F4CDQ39059693-1830F118-5A13-42D3-A246-DED9F4D28888Q39069487-6A3DF3EB-5BFC-41E1-92B7-050A41D9A65FQ39083031-B8D7A29C-8C3A-4BEE-B9C3-F724BFFD24F1Q39306368-E44B119A-8938-4004-8786-85F557B0113B
P2860
Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Prognostic factors for thrombo ...... emia: a study of 605 patients.
@en
Prognostic factors for thrombo ...... emia: a study of 605 patients.
@nl
type
label
Prognostic factors for thrombo ...... emia: a study of 605 patients.
@en
Prognostic factors for thrombo ...... emia: a study of 605 patients.
@nl
prefLabel
Prognostic factors for thrombo ...... emia: a study of 605 patients.
@en
Prognostic factors for thrombo ...... emia: a study of 605 patients.
@nl
P2093
P50
P356
P1433
P1476
Prognostic factors for thrombo ...... hemia: a study of 605 patients
@en
P2093
Cesare Astori
Chiara Elena
Cristiana Pascutto
Elisa Rumi
Emanuela Boveri
Ercole Brusamolino
Mario Lazzarino
Sabrina Boggi
P304
P356
10.3324/HAEMATOL.13346
P577
2008-09-11T00:00:00Z